CM
VNDA icon

Castleark Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Castleark Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-583,960
Closed -$9.31M – 405
2016
Q4 		$9.31M Buy
583,960
+118,415
+25% +$1.9M 0.3% 111
2016
Q3 		$7.75M Buy
+465,545
New +$6.27M 0.23% 135

Other funds holding VNDA

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Castleark Management's VNDA Position: Q1 2017 in Review

Castleark Management sold out of Vanda Pharmaceuticals (VNDA) in Q1 2017, closing a stake of 583,960 shares — an estimated $9.31M sold.

Castleark Management first reported a position in VNDA in Q3 2016 and held it in 2 quarters. The position peaked at $9.31M in Q4 2016. 136 funds tracked by Wall St. Rank hold VNDA as of Q1 2017.

  • Castleark Management reported no remaining Vanda Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Castleark Management sold 583,960 Vanda Pharmaceuticals shares in Q1 2017, an estimated $9.31M.
  • Castleark Management first reported a position in Vanda Pharmaceuticals in Q3 2016 and held it in 2 quarters.
  • Castleark Management's Vanda Pharmaceuticals position peaked at $9.31M in Q4 2016.
  • 136 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2017.

Based on Castleark Management's 13F filing for Q1 2017, filed 15 May 2017.